Comparing the Efficacy and Safety of the Pfizer BNT162b2 Vaccine with Other Alternatives Under COVID-19
DOI:
https://doi.org/10.54097/4dy5rk83Keywords:
COVID-19, Vaccines, Pfizer BNT162b2, Vaccine effectiveness and safety.Abstract
In an epidemic or pandemic caused by a pathogen that has never been encountered, scientists have to compete against time to develop new vaccines. Vaccination effectively prevents the spread of the disease and saves lives. Under the COVID-19 crisis, several types of vaccines were developed and authorized as Emergency Use Authorization (EUA), including the first mRNA vaccine product ever approved by FDA, the BNT162b1. The transiently expressed mRNA does not encounter the problem of genome integration with the host and it takes less time to develop, which differentiates it from alternative types such as inactivated and subunit vaccines. This paper attempts to present the difference of the BNT162b2 mRNA vaccine from the Novavax subunit vaccine, and the Sinovac inactivated vaccine, in terms of COVID-19 prevention and adverse events, therefore attempts to provide a better understanding of the behaviors of mRNA vaccines under COVID-19.
Downloads
References
World Health Organization. Coronavirus disease (COVID-19) pandemic. World Health Organization. 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
World Health Organization. The effects of virus variants on COVID-19 vaccines. World Health Organization. 2021-03-01. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines.
Thorn C R, Sharma D, Combs R, et al. THE JOURNEY OF A LIFETIME – DEVELOPMENT OF PFIZER’S COVID-19 VACCINE. Current Opinion in Biotechnology, 2022, 78: 102803.
Mikulic M. COVID-19 vaccinations administered number by manufacturer U.S. 2021. Statista. 2023-05-02. https://www.statista.com/statistics/1198516/covid-19-vaccinations-administered-us-by-company/.
Vaccine Information Fact Sheet for Recipients and Caregivers about Comirnaty. Pfizer-BioNTech COVID-19 Vaccine. Food and Drug Administration. 2022-12-08.
Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. World Health Organization. 2021-01-14.
Polack F P, Thomas S J, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383 (27): 2603–2615.
Chatzilena A, Hyams C, Challen R, et al. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative case–control study. The Lancet regional health, Elsevier BV, 2023, 25: 100552.
Kadali R A K, Janagama R, Peruru S, et al. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International Journal of Infectious Diseases, 2021, 106: 376–381.
Background document on the Novavax (NVX-CoV2373) vaccine against COVID-19. World Health Organization. 2021-12-20.
Heath P T, Galiza E P, Baxter D N, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 2021, 385.
Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, 2021.
Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. World Health Organization. 2021-05-24.
Zhang W. Sinovac: COVID-19 vaccine production figures 2022. Statista. 2022-05-10/2023-08-18. https://www.statista.com/statistics/1306710/sinovac-covid19-vaccine-production-figures/.
Tanriover M D, Doğanay H L, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 2021, 398 (10296): 213–222.
Tsang N N Y, So H C, Cowling B J, et al. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. The Lancet Infectious Diseases, 2022, 23 (4): 421-434.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
